Half of Youth-Serving Clinicians Screen for Substance Use Disorder at Every Well Visit
By Lori Solomon HealthDay Reporter
THURSDAY, May 22, 2025 -- Just over half of youth-serving clinicians report that they routinely screen adolescents for substance use disorders (SUDs) at every well visit, according to a study published online May 20 in JAMA Network Open.
Kathleen Ragan-Burnett, M.S.P.H., from the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention in Atlanta, and colleagues assessed youth-serving clinicians’ screening, brief intervention, and referral to treatment practices for SUDs among adolescents. The analysis included survey responses from 1,047 youth-serving clinicians.
The researchers found that most clinicians (60.6 percent) reported that skills in SUD diagnosis were relevant to their practice, and 76.4 percent reported seeing at least one adolescent with an SUD monthly. Just over half of clinicians (56.9 percent) reported screening for SUDs at every well visit, with a high proportion of pediatricians reporting screening at every well visit (69.2 percent). Just over one-third of clinicians (39.3 percent) reported screening at every well visit using a screening tool and just under one-third of clinicians (30.7 percent) offered all components of screening, brief intervention, and referral to treatment practice.
"Efforts to improve screening rates through education and systems-based practice changes may facilitate offering anticipatory guidance and SUD treatment in all youth-serving clinical settings," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-23 06:00
Read more

- Multicancer Early Detection Screening Improves Patient Outcomes
- Common Diabetes Drug Effective Against Knee Arthritis Pain
- Socioeconomic Status Tied to New Diagnosis of Hidradenitis Suppurativa
- HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses
- Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
- FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions